Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 17/20 | 1.00 |
| ▸ | CRBN | Q96SW2 | 17/20 | 1.00 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.68 |
| ▸ | TNF | P01375 | 1/20 | 0.68 |
| ▸ | IL1B | P01584 | 1/20 | 0.68 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.68 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15930069 | 1.00 | DDB1 (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL29601554 | 1.00 | DDB1 (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL2110965 | 1.00 | DDB1 (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL1096288 | 1.00 | DDB1 (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL15930063 | 1.00 | DDB1 (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL19611941 | 0.93 | DDB1 (0.87) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL18263911 | 0.93 | DDB1 (0.87) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL18263926 | 0.93 | DDB1 (0.87) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL19359185 | 0.90 | DDB1 (0.82) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL29923364 | 0.90 | DDB1 (0.82) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109678840-B | Preparation method of pomalidomide | 河北菲尼斯生物技术有限公司 | 2023-12-01 | — | — | CN | claimed |
| CN-115572283-A | Pomalidomide feed additive and preparation method and application thereof | 河南湾流生物科技有限公司 | 2023-01-06 | — | — | CN | claimed |
| CN-115557936-A | Preparation method and application of pomalidomide derivative capable of being used as feed additive | 河南湾流生物科技有限公司 | 2023-01-03 | — | — | CN | claimed |
| CN-114605381-A | Preparation method of pomalidomide | 南京海辰药业股份有限公司 | 2022-06-10 | — | — | CN | claimed |
| US-11111228-B2 | Process for the preparation of pomalidomide and its purification | NATCO PHARMA LIMITED (IN) | 2021-09-07 | — | — | US | claimed |
| CN-106565668-B | Preparation method of high-purity pomalidomide | 扬子江药业集团有限公司 | 2020-01-10 | — | — | CN | claimed |
| US-20190233389-A1 | PROCESS FOR THE PREPARATION OF POMALIDOMIDE AND ITS PURIFICATION | NATCO PHARMA LIMITED (IN) | 2019-08-01 | — | — | US | claimed |
| CN-109678840-A | The preparation method of pomalidomide | 河北菲尼斯生物技术有限公司 | 2019-04-26 | — | — | CN | claimed |
| EP-3074383-B1 | IMPROVED PROCESS FOR THE PREPARATION OF POMALIDOMIDE AND ITS PURIFICATION | MYLAN LABORATORIES LTD (IN) | 2018-10-10 | — | — | EP | claimed |
| WO-2018154516-A1 | PROCESS FOR THE PREPARATION OF POMALIDOMIDE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2018-08-30 | — | — | WO | claimed |
| CN-107365295-A | A kind of improved method of pomalidomide synthesis technique | 常州制药厂有限公司 | 2017-11-21 | — | — | CN | claimed |
| US-20170260157-A1 | PROCESS FOR PREPARATION AND PURIFICATION OF POMALIDOMIDE | APICORE US LLC (US) | 2017-09-14 | — | — | US | claimed |
| CN-104926786-B | The preparation method of one kind 3 nitro N (piperidyl of 2,6 dioxo 3) phthalimide | 合肥久诺医药科技有限公司 | 2017-07-28 | — | — | CN | claimed |
| US-20160362391-A1 | Improved Process for the Preparation of Pomalidomide and its Purification | Mylan Laboratories Ltd. (IN) | 2016-12-15 | — | — | US | claimed |
| EP-3074383-A1 | IMPROVED PROCESS FOR THE PREPARATION OF POMALIDOMIDE AND ITS PURIFICATION | Mylan Laboratories Ltd. (IN) | 2016-10-05 | — | — | EP | claimed |
| WO-2015075694-A1 | IMPROVED PROCESS FOR THE PREPARATION OF POMALIDOMIDE AND ITS PURIFICATION | MYLAN LABORATORIES LIMITED (IN) | 2015-05-28 | — | — | WO | claimed |
| EP-4683934-A1 | SYSTEM | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2026-01-28 | — | — | EP | disclosed |
| US-12371426-B2 | Pyridazine derivatives as SMARCA2/4 degraders | AURIGENE DISCOVERY TECH LTD (IN) | 2025-07-29 | — | — | US | disclosed |
| WO-1998003502-A1 | SUBSTITUTED 2(2,6-DIOXOPIPERIDIN-3-YL)PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORPORATION (US) | 1998-01-29 | — | — | WO | disclosed |
| US-5635517-A | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines | CELGENE CORPORATION (US) | 1997-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233389-A1 | PROCESS FOR THE PREPARATION OF POMALIDOMIDE AND ITS PURIFICATION | TNF, HEXD, QDPR | DDB1 3353/4885CRBN 1528/4885IKZF3 2466/4885 |
| US-20160362391-A1 | Improved Process for the Preparation of Pomalidomide and its Purification | HEXD, MGAM, RPN1 | DDB1 4362/4885CRBN 2009/4885IKZF3 3477/4885 |
| US-11111228-B2 | Process for the preparation of pomalidomide and its purification | TNF, QDPR, HEXD | DDB1 3336/4885CRBN 1511/4885IKZF3 2581/4885 |
| US-12371426-B2 | Pyridazine derivatives as SMARCA2/4 degraders | SMARCC1, SMARCC2, SMARCA2 | DDB1 665/4885CRBN 384/4885IKZF3 545/4885 |
| US-20170260157-A1 | PROCESS FOR PREPARATION AND PURIFICATION OF POMALIDOMIDE | QDPR, NQO2, GDI1 | DDB1 3010/4885CRBN 1042/4885IKZF3 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.